2-bromo-6-(bromomethyl)-3-methoxypyridine | 944702-73-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-bromo-6-(bromomethyl)-3-methoxypyridine
• 英文别名: Pyridine, 2-bromo-6-(bromomethyl)-3-methoxy-
• CAS: 944702-73-2
• 化学式: C₇H₇Br₂NO
• 分子量: 280.947
• InChiKey: LFIHYCFTNHIAQQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (1-methyl-1H-5-tetrazolyl)-phenyl-methanone-oxime 、 2-bromo-6-(bromomethyl)-3-methoxypyridine 在 copper(l) iodide 、 四(三苯基膦)钯 、 potassium iodide caesium carbonate 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 24.33h， 生成 N-{[6-(cyclopropylethynyl)-5-methoxypyridin-2-yl]methoxy}-1-(1-methyl-1H-tetrazol-5-yl)-1-phenylmethanimine
  参考文献：
  名称：

  [EN] FUNGICIDE HYDROXIMOYL-TETRAZOLE DERIVATIVES
  [FR] DÉRIVÉS DE L'HYDROXIMOYL-TÉTRAZOLE FONGICIDES

  摘要：

  公开号：

  WO2009115557A3

文献信息

• METHOD FOR ENHANCING ANTI-TUMOR EFFECT OF A MICROTUBULE-TARGETING DRUG, AND A METHOD FOR TREATMENT OF TUMOR
  申请人：TAIHO PHARMACEUTICAL CO., LTD.

  公开号：US20150065479A1

  公开（公告）日：2015-03-05

  A method for treating a tumor by combining a piperidine compound of formula (I) or salt thereof and a microtubule-targeting drug, in which the microtubule-targeting drug is administered once per 7 days or more one cycle, and the piperidine compound is administered once or more per day for 4 days or more: R 1 represents a carboxyl group, —C(═O)NR 5 R 6 , or an oxadiazolyl group optionally substituted with a C 1 -C 6 alkyl group or trifluoromethyl group; R 2 represents a halogen atom or C 1 -C 6 alkoxy group; R 3 represents a phenyl group optionally having 1 to 3 groups, selected from a halogen atom, and a C 1 -C 6 alkyl, C 1 -C 6 alkoxy, or trifluoromethyl group; R 4 represents a hydrogen atom or C 1 -C 6 alkyl group; and R 5 and R 6 , each represent a hydrogen atom, a C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl group; or R 5 and R 6 , together with a nitrogen atom, optionally form a 3 to 6-membered nitrogen-containing saturated heterocyclic group.

  通过结合式(I)的哌啶化合物或其盐和微管靶向药物来治疗肿瘤的方法，其中微管靶向药物每7天或更长周期给药一次，而哌啶化合物每天给药一次或更长周期给药4天或更长周期：R1代表羧基，—C(═O)NR5R6，或者一个可选择地取代有C1-C6烷基或三氟甲基的噁二唑基团；R2代表卤素原子或C1-C6烷氧基团；R3代表苯基，可选择地具有1至3个从卤素原子、C1-C6烷基、C1-C6烷氧基或三氟甲基基团中选择的基团；R4代表氢原子或C1-C6烷基基团；以及R5和R6，各自代表氢原子、C1-C6烷基或C3-C6环烷基团；或者R5和R6，与氮原子一起，可选择地形成一个含氮饱和杂环基团，该基团包括3至6个成员。
• FUNGICIDE HYDROXIMOYL-TETRAZOLE DERIVATIVES
  申请人：Beier Christian

  公开号：US20110105566A1

  公开（公告）日：2011-05-05

  The present invention relates to hydroximoyl-tetrazole derivatives, their process of preparation, preparation intermediate compounds, their use as fungicide active agents, particularly in the form of fungicide compositions and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions.

  本发明涉及羟肟基-四唑衍生物、其制备过程、制备中间体化合物、其作为杀真菌活性剂的用途，特别是作为杀真菌组合物的形式和使用这些化合物或组合物控制植物病原真菌的方法。
• Piperidine compound or salt thereof
  申请人：TAIHO PHARMACEUTICAL CO., LTD.

  公开号：US10092556B2

  公开（公告）日：2018-10-09

  A novel compound which has an excellent aurora A-selective inhibitory action and is useful as an orally administrable anticancer agent is provided. Also, a novel agent for potentiation of anti-tumor effect of microtubule agonists, which include a taxane anticancer agent, and a combination therapy are provided. A piperidine compound represented by a general formula (I) or a salt thereof: wherein, R1 represents a carboxyl group, —C(═O)NR5R6, or an oxadiazolyl group optionally having a C1-C6 alkyl group or a trifluoromethyl group as a substituent; R2 represents a halogen atom or a C1-C6 alkoxy group; R3 represents a phenyl group optionally having 1 to 3 same or different group(s) selected from a halogen atom, a C1-C6 alkyl group, a C1-C6 alkoxy group, and a trifluoromethyl group as a substituent; R4 represents a hydrogen atom or a C1-C6 alkyl group; and R5 and R6 are the same or different and each represent a hydrogen atom, a C1-C6 alkyl group, or a C3-C6 cycloalkyl group, or R5 and R6 optionally form a 3 to 6-membered nitrogen-containing saturated heterocyclic group together with a nitrogen atom to which R5 and R6 are bound, are provided.

  本研究提供了一种新型化合物，它具有出色的极光 A 选择性抑制作用，可用作口服抗癌剂。此外，还提供了一种用于增强微管激动剂（包括一种紫杉类抗癌剂）抗肿瘤作用的新型制剂以及一种联合疗法。一种由通式（I）代表的哌啶化合物或其盐： 其中，R1 代表羧基、-C(═O)NR5R6 或任选具有 C1-C6 烷基或三氟甲基作为取代基的噁二唑基； R2 代表卤素原子或 C1-C6 烷氧基； R3 代表苯基，其取代基可任选具有 1 至 3 个相同或不同的基团，这些基团选自卤素原子、C1-C6 烷基、C1-C6 烷氧基和三氟甲基； R4 代表氢原子或 C1-C6 烷基；以及 R5和R6相同或不同，各自代表氢原子、C1-C6烷基或C3-C6环烷基，或R5和R6可选地与R5和R6所结合的氮原子一起形成3至6元含氮饱和杂环基团。
• NOVEL PIPERIDINE COMPOUND OR SALT THEREOF
  申请人：Taiho Pharmaceutical Co., Ltd.

  公开号：EP2821406B1

  公开（公告）日：2016-06-01
• US8466176B2
  申请人：——

  公开号：US8466176B2

  公开（公告）日：2013-06-18